BSX

$71.20

Market ClosedAs of Mar 17, 8:00 PM UTC

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Zacks
Mar 17, 2026

Why Boston Scientific (BSX) Outpaced the Stock Market Today

Boston Scientific (BSX) closed the most recent trading day at $71.2, moving +2.02% from the previous trading session.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Mar 16, 2026

Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus

Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX) over disclosures about its U.S. Electrophysiology segment. Plaintiffs allege the company misled investors about growth prospects and competitive threats in this business line. The lawsuits follow disappointing financial results and guidance that highlighted pressures in Electrophysiology. Legal claims focus on supposed misrepresentations by company leadership regarding business fundamentals and...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 15, 2026

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement

This medical technology firm delivers advanced noninvasive monitoring and automation solutions to healthcare providers worldwide.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.